Finanzas de Eupraxia Pharmaceuticals Inc (EPRX)EPRXEupraxia Pharmaceuticals Inc

Evaluating the bottom line, Eupraxia Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -108.45%, provide a clear picture of how effectively EPRX converts its operational activities into shareholder value.

In the context of the broader market, EPRX competes directly with industry leaders such as DSGN and SLDB. With a market capitalization of $453.92M, it holds a significant position in the sector. When comparing efficiency, EPRX's gross margin of N/A stands against DSGN's N/A and SLDB's N/A. Such benchmarking helps identify whether Eupraxia Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eupraxia Pharmaceuticals has reported widening net losses, with Q1 2026 showing a net loss of $12.7 million, up from $6.8 million in Q1 2025. The company has a current ratio of 19.30, indicating strong liquidity, but is still facing significant operational losses.